Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Antimicrobial and anti-inflammatory activities of three halophyte plants from Algeria and detection of some biomolecules by HPLC-DAD.

Chekroun-Bechlaghem N, Belyagoubi-Benhammou N, Belyagoubi L, Mansour S, Djebli N, Bouakline H, Gismondi A, Nanni V, Di Marco G, Canuti L, Canini A, Atik-Bekkara F.

Nat Prod Res. 2019 Aug 22:1-5. doi: 10.1080/14786419.2019.1655413. [Epub ahead of print]

PMID:
31437017
2.

Anti-inflammatory activity of argan oil and its minor components.

Menni HB, Belarbi M, Menni DB, Bendiab H, Kherraf Y, Ksouri R, Djebli N, Visioli F.

Int J Food Sci Nutr. 2019 Aug 8:1-8. doi: 10.1080/09637486.2019.1650005. [Epub ahead of print]

PMID:
31394953
4.

Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective.

Shebley M, Sandhu P, Emami Riedmaier A, Jamei M, Narayanan R, Patel A, Peters SA, Reddy VP, Zheng M, de Zwart L, Beneton M, Bouzom F, Chen J, Chen Y, Cleary Y, Collins C, Dickinson GL, Djebli N, Einolf HJ, Gardner I, Huth F, Kazmi F, Khalil F, Lin J, Odinecs A, Patel C, Rong H, Schuck E, Sharma P, Wu SP, Xu Y, Yamazaki S, Yoshida K, Rowland M.

Clin Pharmacol Ther. 2018 Jul;104(1):88-110. doi: 10.1002/cpt.1013. Epub 2018 Feb 2. Review.

5.

A Quantitative Systems Pharmacology Platform to Investigate the Impact of Alirocumab and Cholesterol-Lowering Therapies on Lipid Profiles and Plaque Characteristics.

Ming JE, Abrams RE, Bartlett DW, Tao M, Nguyen T, Surks H, Kudrycki K, Kadambi A, Friedrich CM, Djebli N, Goebel B, Koszycki A, Varshnaya M, Elassal J, Banerjee P, Sasiela WJ, Reed MJ, Barrett JS, Azer K.

Gene Regul Syst Bio. 2017 Jun 22;11:1177625017710941. doi: 10.1177/1177625017710941. eCollection 2017.

6.

Target-Mediated Drug Disposition Population Pharmacokinetics Model of Alirocumab in Healthy Volunteers and Patients: Pooled Analysis of Randomized Phase I/II/III Studies.

Djebli N, Martinez JM, Lohan L, Khier S, Brunet A, Hurbin F, Fabre D.

Clin Pharmacokinet. 2017 Oct;56(10):1155-1171. doi: 10.1007/s40262-016-0505-1.

7.

Ocular Drug Distribution After Topical Administration: Population Pharmacokinetic Model in Rabbits.

Djebli N, Khier S, Griguer F, Coutant AL, Tavernier A, Fabre G, Leriche C, Fabre D.

Eur J Drug Metab Pharmacokinet. 2017 Feb;42(1):59-68. doi: 10.1007/s13318-016-0319-4.

8.

Physiologically based pharmacokinetic modeling for sequential metabolism: effect of CYP2C19 genetic polymorphism on clopidogrel and clopidogrel active metabolite pharmacokinetics.

Djebli N, Fabre D, Boulenc X, Fabre G, Sultan E, Hurbin F.

Drug Metab Dispos. 2015 Apr;43(4):510-22. doi: 10.1124/dmd.114.062596. Epub 2015 Jan 21.

PMID:
25609219
9.

In vivo antiinflammatory activity and chemical composition of Hypericum scabroides.

Mansour S, Djebli N, Ozkan EE, Mat A.

Asian Pac J Trop Med. 2014 Sep;7S1:S514-20. doi: 10.1016/S1995-7645(14)60283-2.

10.

In vitro activity of natural honey alone and in combination with curcuma starch against Rhodotorula mucilaginosa in correlation with bioactive compounds and diastase activity.

Ahmed M, Djebli N, Aissat S, Khiati B, Meslem A, Bacha S.

Asian Pac J Trop Biomed. 2013 Oct;3(10):816-21. doi: 10.1016/S2221-1691(13)60161-6. Epub 2013 Sep 4.

11.

Effects of omeprazole and genetic polymorphism of CYP2C19 on the clopidogrel active metabolite.

Boulenc X, Djebli N, Shi J, Perrin L, Brian W, Van Horn R, Hurbin F.

Drug Metab Dispos. 2012 Jan;40(1):187-97. doi: 10.1124/dmd.111.040394. Epub 2011 Oct 17.

PMID:
22004687
12.

Circadian time-effect of orally administered loratadine on plasma pharmacokinetics in mice.

Dridi D, Ben-Attia M, Sani M, Djebli N, Sauvage FL, Boughattas NA.

Chronobiol Int. 2008 Jul;25(4):533-47. doi: 10.1080/07420520802257646.

PMID:
18622814
13.

[Pharmacogenetics and immunosuppressor drugs: impact and clinical interest in transplantation].

Marquet P, Djebli N, Picard N.

Ann Pharm Fr. 2007 Nov;65(6):382-9. Review. French.

PMID:
18079670
14.

Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients.

Djebli N, Picard N, RĂ©rolle JP, Le Meur Y, Marquet P.

Pharmacogenet Genomics. 2007 May;17(5):321-30.

PMID:
17429314
15.

Metabolism of sirolimus in the presence or absence of cyclosporine by genotyped human liver microsomes and recombinant cytochromes P450 3A4 and 3A5.

Picard N, Djebli N, Sauvage FL, Marquet P.

Drug Metab Dispos. 2007 Mar;35(3):350-5. Epub 2006 Dec 6.

PMID:
17151193
16.

Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients.

Djebli N, Rousseau A, Hoizey G, Rerolle JP, Toupance O, Le Meur Y, Marquet P.

Clin Pharmacokinet. 2006;45(11):1135-48.

PMID:
17048977
17.

CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients.

Le Meur Y, Djebli N, Szelag JC, Hoizey G, Toupance O, RĂ©rolle JP, Marquet P.

Clin Pharmacol Ther. 2006 Jul;80(1):51-60.

PMID:
16815317
18.

In vitro metabolism study of buprenorphine: evidence for new metabolic pathways.

Picard N, Cresteil T, Djebli N, Marquet P.

Drug Metab Dispos. 2005 May;33(5):689-95. Epub 2005 Mar 2.

PMID:
15743975

Supplemental Content

Loading ...
Support Center